150 related articles for article (PubMed ID: 1760808)
1. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
Leung KH
Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
[TBL] [Abstract][Full Text] [Related]
2. Human lymphokine-activated killer (LAK) cells. I. Depletion of monocytes from peripheral blood mononuclear cells by L-phenylalanine methyl ester: an optimization of LAK cell generation at high cell density.
Leung KH
Cancer Immunol Immunother; 1989; 30(4):247-53. PubMed ID: 2598193
[TBL] [Abstract][Full Text] [Related]
3. Generation of human LAK cells in tissue culture bags using recombinant IL-2 and serum free medium. Effects of pretreatment with phenylalanine-methylester.
Wersäll P; Masucci G; Pihlstedt P; Cotgreave I; Tribukait B; Ullberg M; Wigzell H; Mellstedt H
Acta Oncol; 1990; 29(4):431-7. PubMed ID: 2390269
[TBL] [Abstract][Full Text] [Related]
4. Human monocytes inhibit lymphokine-activated killer cell expansion in vitro.
Triozzi PL; Aldrich WA; Rinehart JJ
Mol Biother; 1991 Mar; 3(1):22-5. PubMed ID: 2069757
[TBL] [Abstract][Full Text] [Related]
5. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
6. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
8. Human lymphokine-activated killer (LAK) cells--II. Studies of various L-amino acid methyl esters on LAK generation at high cell density.
Leung KH
Int J Immunopharmacol; 1991; 13(4):401-9. PubMed ID: 2050444
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of protease inhibitors on murine natural killer cell activity.
Ristow SS; Starkey JR; Hass GM
Immunology; 1983 Jan; 48(1):1-8. PubMed ID: 6848446
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
11. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
12. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565.
Sodhi A; Basu S
Nat Immun; 1992; 11(2):105-16. PubMed ID: 1498519
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Itoh K; Pellis NR; Balch CM
Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
[TBL] [Abstract][Full Text] [Related]
16. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
17. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
18. Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells.
Yamauchi A; Bloom ET
J Immunol; 1993 Nov; 151(10):5535-44. PubMed ID: 8228244
[TBL] [Abstract][Full Text] [Related]
19. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events.
Yamauchi A; Taga K; Mostowski HS; Bloom ET
Blood; 1996 Jun; 87(12):5127-35. PubMed ID: 8652825
[TBL] [Abstract][Full Text] [Related]
20. Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon-gamma, natural killer, and lymphokine-activated killer activity by IL-12 in cord blood mononuclear cells.
Lee SM; Suen Y; Chang L; Bruner V; Qian J; Indes J; Knoppel E; van de Ven C; Cairo MS
Blood; 1996 Aug; 88(3):945-54. PubMed ID: 8704253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
